Get started

Stocksignal

TSM: Growth and Charts Align for 15%+ Target?Hey Realistic Traders, Will NYSE:TSM Create a New All-Time High? Let’s Dive In.... TSMC is the world’s largest contract chipmaker. Recent Earning Call reported whooping third quarter revenue of $759.69 billion, marking a YoY increase of 36.5%. The performance is beating the market forecast. Double Digit Revenue Growth is driven by demand for AI Chips especially with major client like NVIDIA & Apple and 3-nanometer &5 nanometer technology in Smartphones. TSMC Chief Financial Officer Huang Renzhao shared optimistic project for the company. TSMC expect Q4 quarterly revenue growth of approximately 13%, sligtly above the market the market expectation. Strong AI-Related demand predicted to persist for year, inlined with the company’s perfomance and expectation. The positive sentiment support our bullish call on NVIDIA. Technical Analysis On the daily timeframe, TSM has remained above the EMA200 line for over a year, maintaining its bullish trend. On August 5, 2024, TSM rebounded impulsively from the EMA200 line after completing an ABC correction pattern, signaling the start of a new bullish wave. The second and fourth corrective waves have retraced to the Fibonacci 0.382 and 0.618 golden ratios, respectively, aligning with Elliott Wave rules that typically indicate further upward movement. In addition to the Elliott Wave analysis, a breakout from a Descending Broadening Wedge pattern has been identified. Such breakouts often signal the continuation of the prevailing market trend. Therefore based on these technical analysis, I foresee a potential upward movement toward the first target at $217.85 or second target at 234.46 This outlook remains valid as long as the price holds above the stop-loss level at 177.95 Support the channel by engaging with the content, using the rocket button, and sharing your opinions in the comments below. Disclaimer: "Please note that this analysis is solely for educational purposes and should not be considered a recommendation to take a long or short position on Taiwan Semiconductor."
NYSE:TSMLong
by financialfreedomgoals101
S&P 500 Index→Simple Analysis SP:SPX The S&P500 index (SPX) has had an excellent run since the time (August 28, see chart below) we introduced the following piece of analysis on the similarities between the 2015 - 2017 fractal and today's 2022 - 2024: If it continues to replicate the past pattern into the 2018 fractal as well, then we may experience the last correction of the Bull Cycle around March 2025 towards the 1W MA50 (blue trend-line) as it happened in February - March 2018 and then the final rally to a new All Time High (ATH) towards the end of the year (October - December 2025). What this pattern shows, and what we've presented to you as a possible scenario on previous analyses, is for a new Bear Cycle to begin in 2026, four years after the Inflation Crisis of 2022, that will once more test the 1W MA200 (orange trend-line), which is the market's long-term Support. As a side-note to investors, it is important to understand that corrections are cyclical and crises systemic. Long-term, multi-year patterns like this, help us understand with a certain degree of efficiency, when to enter and when to exit. Timing is at times (especially on such long-term horizons), more important than pricing.
SP:SPX
by MarketAnalyzar
From Market Underdog to Tech Titan| AppLovin’s Explosive Growth AppLovin: Making Ads Great Again, One Algorithm at a Time AppLovin Corp, a prominent software company valued at $57 billion, offers an advanced mobile marketing platform. Over the past year, its stock price has surged by an impressive 500%, far outpacing the S&P 500’s 39% increase. The company’s financial growth is equally remarkable, with a year over year revenue boost of 40%, a 188% jump in operating profits, and a 300% surge in net income in its latest quarterly report With 40% of the company held by insiders and a shareholder friendly stance that includes share buybacks, AppLovin presents a compelling investment opportunity. Additionally, its valuation remains competitive relative to other software companies, supporting my "buy" rating. From Ad Nerds to Tech Lords, AppLovin’s Secret to Winning Over Wall Street AppLovin operates a comprehensive software platform that helps clients achieve crucial KPIs, such as revenue growth and business expansion. Leveraging AI, its software platform stands out as a powerful tool for advertisers, providing capabilities like automated marketing, customer engagement, and monetization. It’s built to optimize targeted content delivery to the most suitable audience, supported by analytics and monetization features that drive maximum value. At the core of AppLovin’s technology is AXON, an AI engine that powers AppDiscovery. This feature matches advertiser demand with publishing opportunities through a sophisticated real-time auction algorithm, shifting from traditional waterfall systems to an intelligent, programmatic approach. AppLovin has positioned itself as a leader in the future of advertising, driven by its cutting-edge AI capabilities. I believe there’s immense growth potential here that the company is just beginning to explore. Performance In the third quarter, AppLovin reported a 39% year-over-year revenue increase, moving from $864 million to $1.2 billion. This marks its highest-ever quarterly revenue and extends its streak of sequential topline gains to seven quarters. For the first nine months of 2024, AppLovin saw a 43% year-to-date revenue increase, largely fueled by a 76% rise in software platform revenue. This growth was driven by AppDiscovery, whose installations surged by 39% in Q3, underscoring its strong appeal to advertisers. Beyond software platform growth, AppLovin’s in-app purchases and advertising revenues also increased modestly by 3% and 7%, respectively, despite challenging comparisons, supported by a 53% boost in advertising impressions. The company achieved record operating cash flows of over $550 million in Q3, alongside significant margin improvements across gross, operating, and EBITDA levels. These gains highlight the company’s explosive growth and underscore the stock’s 500% rise over the past year. Given AppLovin’s strategic success and positive advertiser response, I anticipate ongoing improvements in cash flow and profit margins. With over $3.3 billion spent on share buybacks since 2022—$980 million in 2024 alone—the company continues to reward its shareholders while capitalizing on its profitable AI-driven platform. Valuation Although APP’s trailing P/E ratio of 74.52 and PS ratio of 19.33 might appear high compared to the IT sector averages, a comparison with peers in the Application Software industry reveals a different perspective. In a peer group of large software companies, APP ranks third in EV/Sales ratio at 18.65 but also boasts a forward topline growth rate of over 24.1%, placing it among the top performers. This high growth potential appears to justify the stock’s premium, positioning it attractively in terms of PS ratio relative to anticipated growth. Despite recent heavy buying, APP remains an appealing value investment. As long as it maintains its relative positioning, I continue to view the stock favorably. Risks Despite my optimism, I recognize that AppLovin’s momentum could be part of a broader AI-driven market surge, raising concerns about a potential AI bubble. If the market faces a downturn similar to the dot-com bubble, APP could experience a sharper decline than its peers, especially given its relatively weak balance sheet. Additionally, with an RSI of 96 signaling heavy overbuying, there may be potential for a future correction. While APP’s 500% rise is impressive, it could be vulnerable if the market undergoes a broader correction Conclusion Advertising is on the cusp of an AI driven transformation, and AppLovin is well-positioned to capitalize on this shift with its powerful AI-enabled platform. Despite the stock’s impressive 12-month performance, there’s still significant growth potential
NASDAQ:APPLong
by moonypto
2
Indian hotels on a high. Indian Hotels Co. Ltd. engages in the ownership, operation, and management of hotels, palaces, and resorts. It operates through India and Overseas geographical segments. Indian Hotels Co. Ltd. CMP is 691.25. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, Strong cash generating ability from core business and Book Value per share Improving for last 2 years. The Negative aspects of the company are High Valuation (P.E. = 76.6), Declining profits and Increasing Trend in Non-Core Income. Entry can be taken after closing above 693 Targets in the stock will be 706 and 722. The long-term target in the stock will be 738. Stop loss in the stock should be maintained at Closing below 649 or 596 depending upon your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:INDHOTELLong
by Happy_Candles_Investment
Vimta Labs trying to be victorious.Vimta Labs Ltd. engages in the provision of contract research and testing. It services include cGMP laboratory services; analytical food and water; preclinical research; clinical research; biopharma; environmental assessments; and clinical reference lab. Vimta Labs Ltd. CMP is 558.20. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, Mutual Funds Increased Shareholding in Past Month and Good Aggregate Candlestick Strength. The Negative aspects of the company are High Valuation (P.E. = 30.2), Declining Net Cash Flow and Inefficient use of assets to generate profits. Entry can be taken after closing above 569 Targets in the stock will be 599, 617 and 643. The long-term target in the stock will be 667 and 702. Stop loss in the stock should be maintained at Closing below 517 or 503 depending upon your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:VIMTALABSLong
by Happy_Candles_Investment
Titagarh Rail systems catching the train. Titagarh Rail Systems Ltd. operates as a holding company, which engages in the manufacture and sale of freight wagons, passenger coaches, and steel castings. It operates through the following segments: Freight Rolling Stock, Passenger Rolling Stock, Shipbuilding, and Others. The Others segment includes miscellaneous items like specialized equipment's for defence, bridge girders, tractors, and others. Titagarh Rail Systems Ltd CMP is 1197.50. The positive aspects of the company are Company with Low Debt, Rising Net Cash Flow and Cash from Operating activity, Annual Profit Growth higher than Sector Profit Growth AND Strong Annual EPS Growth. The Negative aspects of the company are High PE (PE=55.3), High promoter stock pledges AND Companies seeing significant coronavirus impact. Entry can be taken after closing above 1283. Targets in the stock will be 1338, 1509 AND 1596. The long-term target in the stock will be 1710, 1795 AND 1876. Stop loss in the stock should be maintained at Closing below 1049. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:TITAGARHLong
by Happy_Candles_Investment
1
Kopran can climb further. Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. Kopran Ltd CMP is 320. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, FII / FPI or Institutions increasing their shareholding, Annual Profit Growth higher than Sector Profit Growth AND Mutual Funds Increased Shareholding in Past Month. The Negative aspects of the company are Declining Net Cash Flow : Companies not able to generate net cash AND Stocks in the sell zone based on days traded at current PE and P/BV. Entry can be taken after closing above 321. Targets in the stock will be 330 and 342. The long-term target in the stock will be 352 AND 368. Stop loss in the stock should be maintained at Closing below 291. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:KOPRANLong
by Happy_Candles_Investment
High Dividend yield HPCL wants to fly higher. Hindustan Petroleum Corp. Ltd. engages in the business of refining crude oil and sales of petroleum products. It operates through the Downstream and Others segment. The Downstream segment deals with the refining and marketing of petroleum products; The Other segment engages in exploration and production of hydrocarbons, manufacturing sugar ethanol. Hindustan Petroleum Corp. CMP is 405.85. The positive aspects of the company are cheap Valuation (P.E. = 8.7), Company with Zero Promoter Pledge, Annual Profit Growth higher than Sector Profit Growth, MFs increased their shareholding last quarter and Stocks Outperforming their Industry Price Change in the Quarter. Dividend yield of the company at CMP is 5.2%. The Negative aspects of the company are Increasing Trend in Non-Core Income. Entry can be taken after closing above 409 Targets in the stock will be 416 and 429. The long-term target in the stock will be 447 and 457. Stop loss in the stock should be maintained at Closing below 380 or 363 depending on your risk taking ability. Disclaimer:The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:HINDPETROLong
by Happy_Candles_Investment
BPCL with high dividend yield wants to go higher. Bharat Petroleum Corp. Ltd. is a holding company, which engages in the business of refining of crude oil and marketing of petroleum products. It operates through the Downstream Petroleum and Exploration and Production (E&P) segment. The Downstream Petroleum segment includes the refining and marketing of petroleum products. The E&P segment focuses on hydrocarbons. Bharat Petroleum Corp. CMP is 340.75. The positive aspects of the company are cheap Valuation (P.E. = 7.8), Company reducing Debt, Company with Zero Promoter Pledge, Dividend yield of the company at CMP is 6.2%. and Strong Annual EPS Growth. The Negative aspects of the company are Declining Net Cash Flow : Companies not able to generate net cash, Increasing Trend in Non-Core Income and Companies with growing costs YoY for long term projects. Entry can be taken after closing above 347 Targets in the stock will be 355 and 363. The long-term target in the stock will be 375. Stop loss in the stock should be maintained at Closing below 320 or 293 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:BPCLLong
by Happy_Candles_Investment
Linc trying to link back to good times. Linc Ltd. engages in the manufacture and distribution of ball point pen. Its products include gel pen, ball pen, fountain pen, stationery, notebook, and files and folders. It operates through the Writing Instrument and Stationary segment. The company is the exclusive Indian selling agent of the premium pen range of Mitsubishi Pensils Company, Japan. Linc also have a similar arrangement with Besia, Taiwan to sell non-sharpening pensils and erasers. Linc Ltd CMP is 630.65. The Negative aspects of the company are Declining Net Cash Flow Promoter decreasing their shareholding, The positive aspects of the company are Company with No Debt, Company with Zero Promoter Pledge and FII / FPI or Institutions increasing their shareholding. Entry can be taken after closing above 646. Targets in the stock will be 664, 683 and 700. The long-term target in the stock will be 717, 740 and 760. Stop loss in the stock should be maintained at Closing below 578. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:LINCLong
by Happy_Candles_Investment
CD ProjektWake the F up Samurai, We have a money to burn! CD Projekt is a Polish video game developer, publisher and distributor based in Warsaw, founded in May 1994 most people and investors think investing in Metaverse means you should only buy Meta stock but Metaverse already here and big gaming companies are leading it CD Projekt's three year median payout ratio is a pretty moderate 45%, meaning the company retains 55% of its income. So it seems that CDR is reinvesting efficiently in a way that it sees impressive growth in its earnings and pays a dividend that's well covered. Moreover, CDR is determined to keep sharing its profits with shareholders which we infer from its long history of six years of paying a dividend. Our latest analyst data shows that the future payout ratio of the company is expected to drop to 18% over the next three years. However, CDR's future ROE is expected to decline to 11% despite the expected decline in its payout ratio. We infer that there could be other factors that could be steering the foreseen decline in the company's ROE. On the whole, I feel that CD Projekt's performance has been quite good. Particularly, I like that the company is reinvesting heavily into its business at a moderate rate of return. Unsurprisingly, this has led to an impressive earnings growth. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate not to mention that CYBERPUNK 2077 DLC Phantom Liberty going to release in 2023 and they working on new Witcher game. Witcher3 next gen update was another success and its good time for gamers to play this masterpiece if they looking for some exciting adventure I mange to bought CDR stock at 91$ and any price at this range is a dip and good opportunity for long term investment Happy Christmas chooms!
GPW:CDRLong
by moonypto
1
Canara Bank can become a cool Investment. Canara Bank engages in the provision of commercial banking and financial services. It operates through the following segments: Treasury, Corporate or Wholesale Banking, Retail Banking, and Other Banking Business. Canara Bank CMP is 109.30. The positive aspects of the company are cheap Valuation (P.E. = 6.3), Company with Zero Promoter Pledge, Mutual Funds Increased Shareholding over the Past Two Months, Dividend yield greater than sector dividend yield, Annual Profit Growth higher than Sector Profit Growth and Rising Net Cash Flow and Cash from Operating activity. The Negative aspects of the company are High Interest Payments Compared to Earnings, Stocks Underperforming their Industry Price Change in the Quarter and MFs decreased their shareholding last quarter. Entry can be taken after closing above 109.75. Targets in the stock will be 113, 117 and 122. The long-term target in the stock will be 124 and 129. Stop loss in the stock should be maintained at Closing below 100. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:CANBKLong
by Happy_Candles_Investment
Chembond can bond well in your medium term portfolio.Chembond Chemicals Ltd. engages in the manufacture and sale of specialty chemicals. Its products include water treatment, polymers, construction chemicals, coatings, animal nutrition's, and industrial biotech products. Chembond Chemicals Ltd. CMP is 617.25. The positive aspects of the company are moderate Valuation (P.E. = 19), Company with Low Debt, Book Value per share Improving for last 2 years, Company with Zero Promoter Pledge, Annual Profit Growth higher than Sector Profit Growth and Strong Performer, Under Radar Stocks. The Negative aspects of the company are Fall in Quarterly Revenue, net profit and increase trend of non-core income. Entry can be taken after closing above 624 Targets in the stock will be 656 and 677. The long-term target in the stock will be 706 and 746. Stop loss in the stock should be maintained at Closing below 586 or 553 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:CHEMBONDLong
by Happy_Candles_Investment
HEG may be in last Leg of consolidation before it can move up.HEG Ltd. engages in the manufacture and exporter of graphite electrodes. It operates through the Graphite Electrodes and Power Generation segments. HEG Ltd. CMP is 2069.30 The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, Strong cash generating ability from core business and FII / FPI or Institutions increasing their shareholding. The Negative aspects of the company are High Valuation (P.E. = 40.8), Declining profits every quarter for the past 4 quarters, Stocks Underperforming their Industry Price Change in the Quarter and PE higher compared to Industry PE. Entry can be taken after closing above 2089 Targets in the stock will be 2200, 2306, 2406, 2502 and 2565. The long-term target in the stock will be 2622, 2658 and 2750. Stop loss in the stock should be maintained at Closing below 1997 or 1922 depending on your risk taking ability. Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:HEGLong
by Happy_Candles_Investment
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment. Why Wall Street's bullish in this drug company ? First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity. However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders. Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases. For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients. Teva Pharmaceutical's financial performance and 2024 outlook After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million. Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents. What factors contribute to Teva Pharmaceutical's success? To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments. We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter. First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market. In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter. What factors led to the recovery of Teva's generics business? The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio. The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow. Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea. I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia. However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million. Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event. Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars. For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy. However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX). Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase. However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China. The question arises: "Are there any positives?" The short answer is yes. Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter. What is driving this sales growth? Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices. Now lets talk about Risks Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis. In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance. With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits. To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance. The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market. So TEVA Pharmaceutical is a BUY? YUP
NYSE:TEVALong
by moonypto
Asian Paints can rally on low crude oil price. Asian Paints Ltd. manufactures and markets paints and coating products. Asian Paints CMP is 3101.75. The positive aspects of the company are Company with Low Debt, Annual Net Profits improving for last 2 years, FII / FPI or Institutions increasing their shareholding AND MFs increased their shareholding last quarter. The Negative aspects of the company are High PE (PE=58.6), Declining Net Cash Flow : Companies not able to generate net cash, Highest increase in pledges by promoters AND Companies with growing costs YoY for long term projects. Partial entry/tracking quantity can be taken after closing above 3105. Main entry can be taken after closing above 3152. Targets in the stock will be 3221 AND 3304. The long-term target in the stock will be 3368 AND 3423. Stop loss in the stock should be maintained at Closing below 2848 or 2671 depending upon your risk taking ability. Asian paints is considered by many as a portfolio stock due to its huge market share and deep penetration in the market. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ASIANPAINTLong
by Happy_Candles_Investment
Jammu & Kashmir Bank looking NorthwardsJammu & Kashmir Bank Ltd. CMP 117 engages in the provision of banking and financial services. The firm's products and services include personal loans, personal accounts, term bank deposits, mutual fund, life insurances, business loans, business accounts, and business insurance. It operates through the following segments: Treasury Operations, Corporate and Wholesale Banking, Retail Banking, and Other Banking Business. The positive aspects of the company are Company with Low Debt, Annual Net Profits improving for last 2 years, Company with Zero Promoter Pledge and FII / FPI or Institutions increasing their shareholding. Stocks Underperforming their Industry Price Change in the Quarter, Declining Net Cash Flow and MFs decreased their shareholding last quarter. Entry can be taken after closing above 124. Targets in the stock will be 131 and 138. The long-term target in the stock will be 144 and 152. Stop loss in the stock should be maintained at Closing below 102. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:J&KBANKLong
by Happy_Candles_Investment
Delhivery can deliver post a good resultDelhivery Ltd. CMP is 416.10. engages in the provision of logistics solutions to eCommerce partners. It involves in building the operating system for commerce, through a combination of infrastructure, logistics operations, and cutting-edge engineering and technology capabilities. It offers express parcel, partial-truckload, freight, truckload freight, cross-border, and supply chain services. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, MFs increased their shareholding last quarter, Annual Net Profits improving for last 2 years and with increasing Profit Margin (QonQ). The Negative aspects of the company are negative Valuation (P.E. =-292), and Declining Net Cash Flow. Entry can be taken after closing above 422. Targets in the stock will be 434 and 457. The long-term target in the stock will be 476 and 487. Stop loss in the stock should be maintained at Closing below 396 or 368 depending on your risk taking ability. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:DELHIVERYLong
by Happy_Candles_Investment
Ubisoft Entertainment SA / UBIUbisoft Entertainment aka ubi "bug" is a french video game publisher headquartered in Saint-Mandé with development studios across the world. Its video game franchises include Assassin's Creed, Far Cry, For Honor, Just Dance, Prince of Persia, Rabbids, Rayman, Tom Clancy's, and Watch Dogs. Ubisoft was one early investors in web3 technologies and projects too last year was a terrible year for ubi because not only they didn't succeed with their franchise like farcry 6 but also they entered the bear market while they were working on their bigger projects like AC. “We are clearly disappointed by our recent performance,” said Ubisoft Chief Executive Yves Guillemot. “We are facing contrasted market dynamics as the industry continues to shift towards mega-brands and everlasting live games, in the context of worsening economic conditions affecting consumer spending.” 2023 is a big year for ubi and they are going to publish some of their best games like Assassin's Creed Mirage, Tom Clancy’s The Division Heartland and skull and bones ubi stock now in Accumulation phase and its next targets are 21, 23 and 25
LSIN:0NVLLong
by moonypto
1
Astec Lifesciences trying to close above mid channel resistnace.Astec LifeSciences Ltd. engages in the manufacture and sale of agrochemicals and pharmaceutical intermediates. Its products include Tebuconazole, Propiconazole, Hexaconazole, and Difenoconazole. Astec LifeSciences Ltd CMP is 1287.05. The positive aspects of the company are Growth in Net Profit with increasing Profit Margin (QoQ) and Company with Zero Promoter Pledge. The Negative aspects of the company are MFs decreased their shareholding last quarter, Degrowth in Revenue and Profit and Annual net profit declining for last 2 years. Entry can be taken after closing above 1309. Targets in the stock will be 1356 and 1406. The long-term target in the stock will be 1469. Stop loss in the stock should be maintained at Closing below 1247. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ASTECLong
by Happy_Candles_Investment
Escorts Kubota trying to bounce after fall and consolidation. Escorts Kubota Ltd. manufactures and supplies agricultural machinery, auto suspension and ancillary products and railway equipment. It operates through the following segments: Agri Machinery Products, Construction Equipment, Railway Equipment and Others. The Agri Machinery Products segment manufactures tractors, lubricants, engine and gensets; and provides crop solutions. The Construction Equipment segment manufactures and markets construction and material handling equipment like cranes, loaders, vibratory rollers, and forklifts. The Railway Equipment segment manufactures railway components, which includes brakes and brake systems, couplers, rail fastening systems, and automatic twist locks. Escorts Kubota Ltd CMP is 4014.95. The positive aspects of the company are Company with Low Debt, Company with Zero Promoter Pledge, FII / FPI or Institutions increasing their shareholding AND MFs increased their shareholding last quarter. The Negative aspects of the company are High PE (PE=42.3), Declining Net Cash Flow : Companies not able to generate net cash, Companies with high market cap, lower public shareholding AND Increasing Trend in Non-Core Income. Entry can be taken after closing above 4020. Targets in the stock will be 4081 and 4191. The long-term target in the stock will be 4305. Stop loss in the stock should be maintained at Closing below 3855. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:ESCORTSLong
by Happy_Candles_Investment
APPLE (AAPL)Apple's innovation shown in iPhone 14 is not likely enough to entice consumers to stretch their budgets in the current macroeconomic environment 40% of Warren Buffett portfolio still belongs to Apple?! for most people and traders I think its a slow asset class and like Tim Apple! sorry Cook ,Warren like to play safe too Apple price showed a good reaction to 135 support and now heading to 149, for Scalpers breaking 150 resistance can be a good long opportunity and for investors AAPL still can back to 125$ levels so there is no reason to fomo
NASDAQ:AAPLLong
by moonypto
2
Shree Cement looking strong on charts supported by volumesShree Cement Ltd. engages in the manufacturing of cement and cement-related products. The company's brand names include Shree Ultra, Bangur, and Rock Strong. The firm's products include: Ordinary Portland Cement, Portland Pozzolona Cement, Portland Slag Cement, and Composite Cement. CMP of the stock is Rs.25746.55. The Negative aspects of the company are Companies with growing costs YoY for long term projects , High PE (PE > 40), MFs decreased their shareholding last quarter and Declining cash from operations annual. The company's Positive aspects are No debt, Zero promoter pledge, Improving annual net profit. Entry can be taken after closing above 25835. Targets in the stock will be 26000, 26733 and 27283. The long-term target in the stock will be 28317, 29210 and 30754. Stop loss in the stock should be maintained at Closing below 23767. The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
NSE:SHREECEM
by Happy_Candles_Investment